Teneligliptin Tablets

Mechanism

Teneligliptin inhibits DPP‑4 enzyme, prolonging the activity of incretin hormones (GLP‑1 and GIP). This increases insulin secretion in a glucose‑dependent manner and reduces glucagon release, improving glycemic control.

Pharmacokinetics

• Absorption: Rapidly absorbed after oral administration; peak plasma concentration reached in 1–2 hours.
• Bioavailability: High oral bioavailability (~85%).
• Distribution: Moderately protein bound (~60–70%).
• Metabolism: Metabolized primarily in the liver via CYP3A4 and partially excreted unchanged.
• Excretion: Eliminated via both renal (~34%) and hepatic (~66%) routes.
• Half-life: Terminal elimination half-life ~20–24 hours, supporting once‑daily dosing.

Side Effects

• Hypoglycemia (rare, usually with sulfonylureas/insulin)
• Headache
• Nasopharyngitis
• Gastrointestinal upset

Contraindication

• Hypersensitivity to Teneligliptin
• Severe renal impairment
• Severe hepatic impairment

Interaction

• CYP3A4 inhibitors (ketoconazole may increase plasma levels)
• CYP3A4 inducers (rifampicin may reduce efficacy)
• Other antidiabetic agents (risk of hypoglycemia when combined)

Warning and Precautions

• Use under medical supervision only
• Monitor renal and hepatic function during therapy
• Adjust dose in elderly patients

Dosage

As directed by the Physician.